Sanne M. Buijs

Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?

Sanne M. Buijs, Stijn L.W. Koolen, Ron H.J. Mathijssen et al. · Drugs · 2024 · 21 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases

Ruben A.G. van Eerden, Nadine L. de Boer, Job P. van Kooten et al. · British journal of surgery · 2023 · 16 citations

Medicine, Oncology, Pharmacokinetics +17

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer

Sanne M. Buijs, Esther Oomen‐de Hoop, C. Louwrens Braal et al. · ESMO Open · 2023 · 14 citations · Full text

Medicine, Endocrinology, Oncology +15

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial

C. Louwrens Braal, Justin D. Westenberg, Sanne M. Buijs et al. · Breast Cancer Research and Treatment · 2022 · 12 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

CBD-oil as a potential solution in case of severe tamoxifen-related side effects

Sanne M. Buijs, C. Louwrens Braal, Stefan A.J. Buck et al. · npj Breast Cancer · 2023 · 10 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13